Sofinnova Partners closes €725m Crossover II Fund

Image: Envato

Sofinnova Partners has announced the final close of Sofinnova Crossover II at €725m.

The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders.

Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialisation. It will also invest in best-in-class companies in the US and other international markets.

Antoine Papiernik, chairman and managing partner of Sofinnova Partners, said: “The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets. Europe is producing a growing number of world-class life sciences companies, and we believe they should have access to investors that can support them through the critical stages of growth and commercialization.”

Sofinnova Crossover I has supported companies that have gone on to achieve value-creating milestones, including LimFlow (acquired by Inari Medical), Calliditas Therapeutics (acquired by Asahi Kasei), Amolyt Pharma (acquired by AstraZeneca), and Abivax (Nasdaq listing).

Kinam Hong, partner at Sofinnova Partners, said:  “We continue to see exceptional opportunities emerging across European life sciences. Many companies now have scientific strength, clinical validation, and leadership teams needed to compete on a global stage. With Sofinnova Crossover II, we are well positioned to support that next generation of leaders while maintaining the disciplined investment approach that defined our first fund.”

The fund has already backed Hemab Therapeutics, CellCentric and Neurent Medical and expects to invest in approximately 15 companies over its investment period, with a primary focus on Europe and selective investments globally.

The strategy is led by Partners Joe Anderson, Kinam Hong, Cedric Moreau, Jacques Theurillat, and David Evans. The fund is backed by the European Tech Champions Initiative (ETCI), a fund of funds managed by the European Investment Fund (EIF).